全年亏损收窄,在研管线有序推进。2024 年公司经调整亏损1.68 亿元,上年同期为亏损2.49 亿元,全年亏损收窄。2024 全年研发开支为1.35 亿元(同比-21.7%),主要由于随着LZ901 国内Ph3 临床进展,相关折旧摊销减少,同时以股份付款的员工成本减少等原因;行政开支为0.87 亿元(同比-25.5%),主要由于以股份付款的员工成本减少。LZ901(重组带状疱疹疫苗):于2023...
Source Link全年亏损收窄,在研管线有序推进。2024 年公司经调整亏损1.68 亿元,上年同期为亏损2.49 亿元,全年亏损收窄。2024 全年研发开支为1.35 亿元(同比-21.7%),主要由于随着LZ901 国内Ph3 临床进展,相关折旧摊销减少,同时以股份付款的员工成本减少等原因;行政开支为0.87 亿元(同比-25.5%),主要由于以股份付款的员工成本减少。LZ901(重组带状疱疹疫苗):于2023...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.